German maker of glass and polymer packaging such as vials, syringes and cartridges used to package injectable drugs.
German maker of glass and polymer packaging such as vials, syringes and cartridges used to package injectable drugs.
Sells vials, syringes and cartridges to drug makers in high volumes under supply agreements, as part of the approved drug's registered packaging, so changing supplier means re-approval and customers rarely switch. It is the pharmaceutical packaging arm of the SCHOTT glass group, which keeps the majority and listed it in 2023.
In one line: A German West Pharmaceutical Services/Gerresheimer peer.
Moat: narrow (regulatory licence, customer qualification, process know-how). Pharma-grade glass/polymer manufacturing with long customer qualification cycles, benefiting from GLP-1/biologics packaging demand.
Headquarters: Mainz, Germany · Founded: 2020 · Employees: 4,811
Size SCHOTT Pharma AG & Co. KGaA (1SXP.DE) is a Germany Health Care company (Medical Specialties) with a market value of $3.73B, the 81st largest of 198 Germany companies the cockpit tracks. Shares closed at €22.60 on 18 Nov 2026.
Performance Over six months the shares gained 32.2%, against +3.2% for the median peer and -0.9% for the Germany market (cap-weighted) — 7th highest of 21 in its peer set.
Growth Revenue grew 4.3% over the last twelve months (peer median +7.4%); the operating margin is 15.5% (peer median 11.6%).
Valuation It trades at 23.0× forward earnings against a peer median of 24.4× (10th cheapest of 20).
Price implies For today's price to make sense, revenue must grow about 13% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is +2 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 4.0 points above its cost of capital (7.4% WACC).
Next results Next results expected around 10 Dec 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €1.02B | €986M | €957M | €899M | €821M |
| Revenue growth | — | +3% | +7% | +9% | — |
| Gross profit | €317M | €332M | €323M | €315M | €295M |
| EBITDA | €245M | €255M | €238M | €211M | €217M |
| Net income | €137M | €146M | €150M | €152M | €125M |
| Free cash flow | €55.3M | €35.6M | €79.7M | €6.18M | €30.1M |
| Capital expenditure | €138M | €145M | €145M | €176M | €153M |
| Total debt | €0 | €83.0M | €85.8M | €72.3M | €74.8M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| SCHOTT Pharma AG & Co. KGaA 1SXP.DE | $3.73B | +32% | +4% | 15% | 23.0× | 12.7% |
| Gerresheimer GXI.DE | $1.26B | +21% | +9% | -4% | 16.0× | 57.0% |
| West Pharmaceutical Services WST | $28.1B | +32% | +13% | 23% | 40.2× | 25.8% |
| Corning GLW | $93.2B | -40% | +19% | 17% | 25.7× | 25.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 1SXP.DE | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -13.1% | +5.3% | 4th lowest of 21 |
| 6-month return | +32.2% | +3.2% | 7th highest of 21 |
| Distance from 52-week high | -13.7% | -24.1% | 6th highest of 21 |
| Revenue growth (TTM) | +4.3% | +7.4% | 10th lowest of 21 |
| Operating margin | 15.5% | 11.6% | 4th highest of 20 |
| Forward P/E | 23.0× | 24.4× | 10th cheapest of 20 |
| Growth the price implies (Req g, 7 yrs) | 12.7% | 10.0% | 8th most demanding of 18 |
| Growth delivered (Del g) | +11.0% | +8.9% | 7th highest of 18 |
| Hurdle (Req g minus delivered) | +1.6 pp | +1.0 pp | 8th most demanding of 18 |
| ROIC minus cost of capital | +4.0 pp | -1.1 pp | 4th highest of 19 |
| EV / EBITDA | 13.8× | 13.3× | 6th cheapest of 11 |
| Net debt / EBITDA | -0.1× | 1.1× | 4th least indebted of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| SCHOTT Pharma AG & Co. KGaA 1SXP.DE | Germany | $3.73B | +32% | +4% | 15% | 23.0× | 12.7% | +11.0% |
| Envista NVST | United States | $3.81B | 0% | +10% | 12% | 14.7× | 4.8% | +7.1% |
| Shandong Weigao Blood Purification Products 603014.SS | China | $3.63B | -1% | +4% | n/a | 20.4× | -1.2% | +8.1% |
| Andon Health 002432.SZ | China | $3.86B | -24% | -30% | -26% | 16.1× | -6.6% | -7.4% |
| Tecan TECN.SW | Switzerland | $3.60B | +59% | -4% | 1% | 35.5× | 45.4% | +3.8% |
| CareDx CDNA | United States | $3.91B | +252% | +39% | 1% | 50.6× | n/a | n/a |
| Fielmann FIE.DE | Germany | $3.92B | -3% | +3% | 14% | 17.1× | -5.5% | +11.3% |
| Sumitomo Bakelite 4203.T | Japan | $3.50B | +7% | +15% | 13% | 15.9× | 8.6% | +8.9% |
| Ambu A/S AMBU-B.CO | Denmark | $3.47B | +31% | +7% | 13% | 28.8× | 10.0% | +10.0% |
| Axogen AXGN | United States | $3.40B | +33% | +24% | -5% | 87.3× | 52.6% | +14.9% |
| Pulse Biosciences PLSE | United States | $3.37B | +76% | +1,637% | -5,821% | n/a | n/a | n/a |
| Autobio Diagnostics 603658.SS | China | $3.36B | +16% | +3% | 25% | 20.3× | -0.4% | +7.2% |
| TransMedics TMDX | United States | $3.35B | +42% | +28% | 12% | 43.4× | 38.4% | +88.2% |
| Jiangsu Yuyue Medical Equipment & Supply 002223.SZ | China | $4.18B | -3% | -1% | 13% | 20.0× | 4.9% | +3.4% |
| Stevanato STVN | United States | $4.19B | -13% | +12% | 18% | 22.5× | 13.1% | +12.1% |
| iRay Technology 688301.SS | China | $3.31B | -30% | +58% | 24% | 25.7× | n/a | n/a |
| Zhende Medical 603301.SS | China | $3.26B | -10% | +8% | 7% | 42.5× | 22.9% | -16.1% |
| Lepu Medical Technology (Beijing) 300003.SZ | China | $3.20B | -13% | -1% | 13% | 24.4× | 8.7% | -4.2% |
| iRhythm IRTC | United States | $3.19B | -19% | +22% | 5% | 99.8× | 46.9% | +23.0% |
| Carl Zeiss Meditec AFX.DE | Germany | $3.17B | +22% | 0% | 8% | 24.4× | 12.5% | +10.8% |
| ICU Medical ICUI | United States | $4.46B | +38% | -6% | 8% | 19.4× | 18.9% | +11.9% |